Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021-Reference-Cited by-同舟云学术

Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021

Published:2021-04-29 Issue:17 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Fabiani Massimo¹^ORCID,Ramigni Mauro²,Gobbetto Valentina²,Mateo-Urdiales Alberto³¹,Pezzotti Patrizio¹,Piovesan Cinzia²

Affiliation:

1. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

2. Local Health Unit (ULSS 2 Marca Trevigiana), Treviso, Italy

3. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Abstract

Data on effectiveness of the BioNTech/Pfizer COVID-19 vaccine in real-world settings are limited. In a study of 6,423 healthcare workers in Treviso Province, Italy, we estimated that, within the time intervals of 14–21 days from the first and at least 7 days from the second dose, vaccine effectiveness in preventing SARS-CoV-2 infection was 84% (95% confidence interval (CI): 40–96) and 95% (95% CI: 62–99), respectively. These results could support the ongoing vaccination campaigns by providing evidence for targeted communication.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference11 articles.

1. Impact of a nationwide lockdown on SARS-CoV-2 transmissibility, Italy.;Guzzetta;Emerg Infect Dis,2021

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.;Polack;N Engl J Med,2020

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with IgG titers against SARS-CoV-2 spike protein after second vaccination in people living with HIV controlled with anti-retroviral therapy;Journal of Infection and Chemotherapy;2024-01

2. SARS-CoV-2 infection risk in COVISHIELD (AstraZeneca-SII) Vaccinated Healthcare Workers in a Tertiary Cancer Care Centre of North-East India;2023-12-11

3. Characterization of SARS-CoV-2 Variants in Military and Civilian Personnel of an Air Force Airport during Three Pandemic Waves in Italy;Microorganisms;2023-11-05

4. An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines;Biomolecules;2023-10-24

5. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review;Frontiers in Public Health;2023-10-24